文献速递神经肿瘤神经重症

立体定向激光消融治疗放射外科后复发脑转移的系统综述

Stereotactic Laser Ablation as Treatment of Brain Metastases Recurring after Stereotactic Radiosurgery: A Systematic Literature Review.
PubMed 文献 · World Neurosurg · 2019-04-30

局部控制与肿瘤热消融比例相关,完全消融者3个月局部控制率为80%-100%,中位生存5.8-19.8个月,SLA相关永久性神经损伤发生率<10%。结论支持继续发展SLA治疗BMRS,但围手术期管理尚需标准化。

要点

  • 完全消融的BMRS病灶3个月局部控制率达80%-100%,疗效与热消融比例相关。
  • 消融后对比增强体积和FLAIR体积可一过性扩大,最大可超过术前>3倍,多在6个月内消退。
  • SLA相关永久性神经损伤发生率<10%,常见并发症为出血、热损伤致神经功能缺损和恶性脑水肿。

核心结论

  • 分析结果支持继续发展SLA作为放射外科后复发脑转移的治疗选择。
  • SLA的围手术期管理尚需标准化。

研究设计与样本

  • 系统综述,检索PubMed中研究SLA治疗放射外科后复发脑转移的文献。

主要发现

  • 局部控制率取决于肿瘤被热消融的百分比。
  • 完全消融肿瘤的3个月局部控制率为80%-100%。
  • 中位生存期为5.8至19.8个月。
  • 约三分之二的治疗病灶出现消融后对比增强体积和FLAIR体积扩大,扩大可在治疗后1小时内开始,通常在6个月内消退。
  • 最大扩大的对比增强体积可超过术前病灶体积的3倍。

关键数值与推荐

  • 完全消融肿瘤3个月局部控制率为80%-100%。
  • 中位生存期为5.8至19.8个月。
  • 最大扩大对比增强体积可超过术前体积的3倍。
  • SLA相关永久性神经损伤发生率<10%。
  • 中位住院时间1-2天(范围1-5天),出院回家比例59.5%-100%。

临床怎么用

  • SLA可作为放射外科后复发脑转移的潜在治疗选项。
  • 术后应预期对比增强和FLAIR体积一过性扩大,避免误判为肿瘤进展。
  • 围手术期常用地塞米松,但剂量与疗程需个体化并待标准化。

局限性

  • 围手术期地塞米松剂量和疗程存在差异,缺乏统一标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal treatment of brain metastases recurring after radiosurgery (BMRS) remains an area of active investigation. Stereotactic laser ablation (SLA, also known as laser interstitial thermal therapy) has recently emerged as a potential treatment option. OBJECTIVE: To summarize the available literature on SLA as treatment of BMRS and synthesize findings on local control, overall survival, neurologic outcome, imaging findings, morbidity, and postprocedure clinical course. METHODS: We performed a comprehensive search of PubMed for articles investigating SLA as treatment of BMRS. RESULTS: Thirteen peer-reviewed publications met our search criteria. Local control was a function of the percentage of tumor that was thermally ablated. In completely ablated tumors, 3-month local control was 80%-100%. Median survival ranged from 5.8 to 19.8 months. About two-thirds of treated lesions showed postablation expansion of contrast-enhancing volume and fluid-attenuated inversion recovery volume. Expansion could start within an hour of treatment, and resolution typically occurred within 6 months. Notably, maximal expanded contrast-enhancing volume could reach >3-fold the preoperative lesion volume. The incidence of SLA-related permanent neurologic injuries was <10%. The most common complications were hemorrhage, thermal injury causing neurologic deficit, and malignant cerebral edema. Nearly all patients were treated with dexamethasone, but there was variability in the dose and duration of therapy. Median hospital stay was 1-2 days (range, 1-5 days), and most treated patients were discharged home (range, 59.5%-100%). CONCLUSION: Our analysis provides support for continued development of SLA as a treatment of BMRS. Standardization of periprocedural management will be needed.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Alattar AA, Bartek J, Chiang VL, et al. Stereotactic Laser Ablation as Treatment of Brain Metastases Recurring after Stereotactic Radiosurgery: A Systematic Literature Review. World Neurosurg. 2019. PMID: 31051303. doi:10.1016/j.wneu.2019.04.200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。